Attention-deficit-hyperactivity disorder (ADHD) affects over 40 million people—children, adolescents, and adults—across the major pharmaceutical markets. The key treatment goals for both…
MARKET OUTLOOK The accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite…
The treatment of axial spondyloarthritis has been transformed in the last decade by the approval of biologics to treat the disease and the recognition that patients without evidence of radiographic…
Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven significant…
Overall, the renal anemia therapy market will expand over the 2017-2027 study period, fueled by the increasing prevalence of this complication of chronic kidney disease and the emergence of a novel…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key psoriasis patient populations covering 171 countries and more than 99%…
DRG Epidemiology's coverage of psoriasis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsO for each country, as well…
DRG Epidemiology's coverage of psoriasis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsO for each country, as well…
DRG Epidemiology's coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total symptomatic prevalence of PsO…
DRG Epidemiology's coverage of psoriasis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsO for each country, as well…
DRG Epidemiology's coverage of psoriasis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsO for each country, as well…
DRG Epidemiology's coverage of psoriasis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsO for each country, as well…
MARKET OUTLOOK DRG anticipates the next ten years to be an exciting time in the hemophilia A space as the number of treatment options grow for patients with, and without, inhibitors. The…
Patients with osteoporosis are at increased risk of suffering fractures due to a loss in bone strength. These fractures, in turn, place a considerable burden on public health systems. The…
PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless, TNF…